For the quarter ending 2025-09-30, EW had -$595,200K decrease in cash & cash equivalents over the period. $516,200K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net income | 290,300 | 331,500 | 356,400 | 384,300 |
| Depreciation and amortization | 39,200 | 38,100 | 36,600 | 42,600 |
| Non-cash operating lease cost | 6,800 | 6,400 | 6,100 | 6,200 |
| Stock-based compensation (note 9) | 41,200 | 37,500 | 40,200 | 31,700 |
| Gain on sale of business | 0 | - | - | 10,800 |
| Loss on impairment | - | 47,100 | - | 0 |
| Intangible assets impairment charges | 40,000 | - | - | - |
| Change in fair value of contingent consideration liabilities | -12,500 | - | - | 0 |
| Loss (gain) on investments, net | - | - | -12,500 | 5,200 |
| Deferred income taxes | 18,000 | 20,900 | 24,300 | 98,500 |
| Gain on remeasurement of previously held interest upon acquisition | 0 | - | - | 30,400 |
| Loss on impairment | 47,100 | - | - | - |
| Other | 6,000 | -4,700 | -3,600 | -15,700 |
| Accounts and other receivables, net | -13,200 | 24,900 | 43,700 | -105,900 |
| Inventories | 1,800 | -41,600 | 100 | 51,200 |
| Accounts payable and accrued liabilities | 226,100 | 103,700 | -103,400 | -3,100 |
| Income taxes | -10,200 | -240,400 | 51,200 | -488,500 |
| Prepaid expenses and other current assets | 14,200 | 13,900 | -10,600 | 4,700 |
| Long-term prepaid royalties (note 3) | - | - | - | -2,100 |
| Intellectual property agreement accrual | -12,500 | -12,500 | -36,700 | -12,500 |
| Other | 7,900 | -4,700 | 28,600 | 11,100 |
| Net cash provided by operating activities | 573,700 | 290,200 | 280,400 | -127,500 |
| Capital expenditures | 57,500 | 49,300 | 56,000 | 49,800 |
| Investments in unconsolidated affiliates | 1,500 | 46,900 | - | - |
| Purchases of held-to-maturity investments (note 5) | 24,400 | 6,000 | 12,800 | 9,600 |
| Proceeds from held-to-maturity investments (note 5) | 22,200 | 14,300 | 17,700 | 7,100 |
| Purchases of available-for-sale investments (note 5) | 1,006,400 | 624,300 | 634,500 | 381,100 |
| Collections of notes receivable | - | - | - | 0 |
| Proceeds from available-for-sale investments (note 5) | 669,700 | 611,800 | 827,900 | 261,000 |
| Investments in intangible assets | 0 | 0 | 0 | 4,600 |
| Payment for working capital adjustment and sale of product group (note 4) | 0 | 0 | 36,300 | - |
| Business combinations, net of cash | 0 | - | - | 298,200 |
| Payment for acquisition options | 2,600 | 14,000 | 3,000 | 30,000 |
| Proceeds from sale of product group | - | - | - | 0 |
| Issuances of notes receivable | 22,800 | 52,800 | 17,800 | 35,000 |
| Other | 4,500 | 3,500 | -100 | 36,500 |
| Net cash (used in) provided by investing activities | -427,800 | -172,100 | 85,300 | -576,700 |
| Purchases of treasury stock | 588,700 | 5,500 | 258,600 | 100,100 |
| Equity forward contract related to accelerated share repurchase agreement (note 10) | -50,000 | 0 | -50,000 | - |
| Purchase of remaining noncontrolling interest in subsidiary (note 6) | 233,700 | - | - | - |
| Proceeds from stock plans | 34,700 | 57,200 | 49,900 | 28,600 |
| Other | -2,400 | 1,000 | 700 | 100 |
| Net cash used in financing activities | -740,100 | 52,700 | -258,000 | 28,600 |
| Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash | -1,000 | -29,600 | -17,700 | 51,000 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -595,200 | 141,200 | 90,000 | -624,600 |
| Cash and cash equivalents at beginning of period | 3,290,000 | 3,148,800 | 3,058,800 | 3,683,400 |
| Cash and cash equivalents at end of period | 2,694,800 | 3,290,000 | 3,148,800 | 3,058,800 |
Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp (EW)